Chemotherapy in epithelial ovarian cancer

被引：79

作者：

Pignata, Sandro ^{[1
]}

Cannella, Lucia ^{[1
]}

Leopardo, Davide ^{[1
]}

Pisano, Carmela ^{[1
]}

Bruni, Giovanni Salvatore ^{[1
]}

Facchini, Gaetano ^{[1
]}

机构：

[1] Natl Canc Inst Naples, Dept Urol & Gynecol, Div Med Oncol, I-80131 Naples, Italy

来源：

CANCER LETTERS | 2011年 / 303卷 / 02期

关键词：

Ovarian cancer; Chemotherapy; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; PACLITAXEL-RESISTANT OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAPERITONEAL CISPLATIN; INTERGROUP TRIAL; RANDOMIZED-TRIAL; INTRAVENOUS CHEMOTHERAPY; DOCETAXEL-CARBOPLATIN; 1ST-LINE TREATMENT;

D O I：

10.1016/j.canlet.2011.01.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the most common type of ovarian cancer; usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with a poor prognosis. Treatment of ovarian cancer is based on the integration of surgery and chemotherapy. Chemotherapy plays a major role both in the adjuvant treatment and in the care of patients with advanced disease. Several active drugs have been introduced in the treatment of ovarian cancer in the last decades and novel targets and agents are under evaluation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：73 / 83

页数：11

共 86 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[3] IMPACT OF DOXORUBICIN ON SURVIVAL IN ADVANCED OVARIAN-CANCER [J].

AHERN, RP ;

GORE, ME .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :726-732

[4] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[5]

[Anonymous], J CLIN ONCOL S

[6]

[Anonymous], ANN ONCOL S8

[7] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[8] Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer [J].

Belani, Chandra P. ;

Ramalingam, Suresh ;

Perry, Michael C. ;

LaRocca, Renato V. ;

Rinaldi, David ;

Gable, Preston S. ;

Tester, William J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :468-473

[9] Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].

Bell, Jeffrey ;

Brady, Mark F. ;

Young, Robert C. ;

Lage, Janice ;

Walker, Joan L. ;

Look, Katherine Y. ;

Rose, G. Scott ;

Spirtos, Nick M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :432-439

[10] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].

Bookman, Michael A. ;

Brady, Mark F. ;

McGuire, William P. ;

Harper, Peter G. ;

Alberts, David S. ;

Friedlander, Michael ;

Colombo, Nicoletta ;

Fowler, Jeffrey M. ;

Argenta, Peter A. ;

De Geest, Koen ;

Mutch, David G. ;

Burger, Robert A. ;

Swart, Ann Marie ;

Trimble, Edward L. ;

Accario-Winslow, Chrisann ;

Roth, Lawrence M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425

← 1 2 3 4 5 6 7 8 9 →